Durable Goods (Jun F) -9.4% vs 9.3% Prior, Ex-Trans 0.2% vs 0.2%
Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold company shares valued at $181,129. The transactions, executed on February 13, 2025, involved the sale of 796 shares at an average price of $116.77 and 755 shares at $116.80. These sales were conducted under pre-established trading plans. The stock, currently trading near its 52-week low of $110.95, shows signs of being oversold according to InvestingPro analysis.
Despite these sales, Cooke's overall position in the company remains substantial. Following these transactions, she holds 20,190 shares directly. Additionally, Cooke exercised options to acquire 1,509 and 1,401 shares at no cost, maintaining her stake in the company. While trading at a relatively high P/E ratio of 33.9x, InvestingPro data indicates the company maintains excellent financial health with strong liquidity ratios. Analysts have set price targets ranging from $138 to $192, suggesting potential upside from current levels. Get the complete analysis and 10+ additional ProTips with an InvestingPro subscription.
In other recent news, Neurocrine Biosciences has been the subject of multiple analyst reports following its fourth-quarter sales report. Deutsche Bank (ETR:DBKGn) initiated coverage on Neurocrine Biosciences, assigning a Hold rating and a price target of $138, highlighting the company's potential treatments and pipeline developments. UBS, on the other hand, maintained a Buy rating while revising the price target down to $154, expressing confidence in the stock's potential for future gains despite reduced expectations for Ingrezza, Neurocrine's lead product. Guggenheim also maintained a Buy rating but lowered the price target to $163 following the company's fourth-quarter sales report, which showed Ingrezza sales slightly below consensus estimates. H.C. Wainwright adjusted the price target for Neurocrine Biosciences to $185 while maintaining a Buy rating, citing Ingrezza's low market penetration and favorable risk-benefit profile as reasons for continued confidence in the company's stock. These are some of the recent developments involving Neurocrine Biosciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.